Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346

1.

New-onset Diabetes Mellitus as a clue for early pancreatic cancer diagnosis.

Vincenzi B, D'Onofrio L.

Diabetes Metab Res Rev. 2018 Jun 21:e3033. doi: 10.1002/dmrr.3033. [Epub ahead of print] No abstract available.

PMID:
29927040
2.

Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.

Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S.

JAMA Oncol. 2018 Apr 12. doi: 10.1001/jamaoncol.2018.0219. [Epub ahead of print]

PMID:
29800950
3.

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment.

Fioramonti M, Fausti V, Pantano F, Iuliani M, Ribelli G, Lotti F, Pignochino Y, Grignani G, Santini D, Tonini G, Vincenzi B.

Sci Rep. 2018 Mar 8;8(1):4177. doi: 10.1038/s41598-018-22469-5.

4.

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.

Vincenzi B, Badalamenti G, Armento G, Silletta M, Spalato Ceruso M, Catania G, Napolitano A, Maltese G, Valeri S, Incorvaia L, Santini D, Tonini G.

Oncology. 2018;95(1):1-7. doi: 10.1159/000487266. Epub 2018 Mar 6.

PMID:
29510410
5.

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA.

Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19.

6.

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, Vincenzi B, Calò V, Iovanna JL, Bazan V, Russo A.

Cell Immunol. 2018 Jan 30. pii: S0008-8749(18)30014-5. doi: 10.1016/j.cellimm.2018.01.013. [Epub ahead of print] Review.

PMID:
29395859
7.

Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder.

Nemani KL, Greene MC, Ulloa M, Vincenzi B, Copeland PM, Al-Khadari S, Henderson DC.

Clin Schizophr Relat Psychoses. 2017 Nov 22. doi: 10.3371/CSRP.KNMG.111717. [Epub ahead of print]

PMID:
29164928
8.

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.

Rizzo S, Galvano A, Pantano F, Iuliani M, Vincenzi B, Passiglia F, Spoto S, Tonini G, Bazan V, Russo A, Santini D.

Crit Rev Oncol Hematol. 2017 Dec;120:227-233. doi: 10.1016/j.critrevonc.2017.09.008. Epub 2017 Oct 16. Review.

PMID:
29110971
9.

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.

Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G.

Crit Rev Oncol Hematol. 2017 Oct;118:1-6. doi: 10.1016/j.critrevonc.2017.06.006. Epub 2017 Jul 15. Review.

PMID:
28917265
10.

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A.

Oncologist. 2018 Jan;23(1):62-70. doi: 10.1634/theoncologist.2017-0161. Epub 2017 Jul 28.

PMID:
28754721
11.

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.

Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G.

Br J Cancer. 2017 Jul 25;117(3):340-346. doi: 10.1038/bjc.2017.187. Epub 2017 Jun 22.

PMID:
28641307
12.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

13.

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G.

Ann Oncol. 2017 Nov 1;28(11):2906. doi: 10.1093/annonc/mdw551. No abstract available.

PMID:
28327895
14.

Determinants of bone specific metastasis in prostate cancer.

Manca P, Pantano F, Iuliani M, Ribelli G, De Lisi D, Danesi R, Del Re M, Vincenzi B, Tonini G, Santini D.

Crit Rev Oncol Hematol. 2017 Apr;112:59-66. doi: 10.1016/j.critrevonc.2017.02.013. Epub 2017 Feb 16. Review.

PMID:
28325265
15.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
16.

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.

Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, Rea D, Castagnetti F, Hellmann A, Rosti G, Gattermann N, Coronel MLP, Gutierrez MAE, Garcia-Gutierrez V, Vincenzi B, Dezzani L, Giles FJ.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.

17.

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.

Fioramonti M, Santini D, Iuliani M, Ribelli G, Manca P, Papapietro N, Spiezia F, Vincenzi B, Denaro V, Russo A, Tonini G, Pantano F.

Oncotarget. 2017 Mar 21;8(12):20113-20121. doi: 10.18632/oncotarget.15390.

18.

Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.

Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altimari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G.

Mol Cancer Res. 2017 May;15(5):553-562. doi: 10.1158/1541-7786.MCR-16-0376. Epub 2017 Jan 27.

19.

Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.

Del Prete S, Cennamo G, Leo L, Montella L, Vincenzi B, Biglietto M, Andreozzi F, Prudente A, Iodice P, Savastano C, Nappi A, Montesarchio V, Addeo R.

Future Oncol. 2017 Feb;13(5):415-423. doi: 10.2217/fon-2016-0421. Epub 2016 Oct 26.

PMID:
27780365
20.

Dietary Protective Effects Against Hepatocellular Carcinoma Development in Mdr2-/- Knockout Mice.

Gentileschi MP, Lattanzio C, Menicagli F, Vincenzi B, Cigliana G, Baldi A, Blandino G, Muti P, Fanciulli M, Spugnini EP.

In Vivo. 2016 Jul-Aug;30(4):445-50.

PMID:
27381607
21.

Procalcitonin as diagnostic marker of infection in solid tumors patients with fever.

Vincenzi B, Fioroni I, Pantano F, Angeletti S, Dicuonzo G, Zoccoli A, Santini D, Tonini G.

Sci Rep. 2016 Jun 17;6:28090. doi: 10.1038/srep28090.

22.

Drug-induced hepatotoxicity in cancer patients - implication for treatment.

Vincenzi B, Armento G, Spalato Ceruso M, Catania G, Leakos M, Santini D, Minotti G, Tonini G.

Expert Opin Drug Saf. 2016 Sep;15(9):1219-38. doi: 10.1080/14740338.2016.1194824. Epub 2016 Jun 14. Review.

PMID:
27232067
23.

Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.

Vincenzi B, Greene CM, Ulloa M, Parnarouskis L, Jackson JW, Henderson DC.

J Psychiatr Pract. 2016 May;22(3):175-82. doi: 10.1097/PRA.0000000000000149.

24.

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G.

Sci Rep. 2016 Apr 15;6:22205. doi: 10.1038/srep22205. No abstract available.

25.

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.

Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G.

Oncotarget. 2016 May 31;7(22):33381-90. doi: 10.18632/oncotarget.8302.

26.

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A.

Crit Rev Oncol Hematol. 2016 Mar;99:150-7. doi: 10.1016/j.critrevonc.2015.12.015. Epub 2016 Jan 2. Review.

PMID:
26775732
27.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G.

Sci Rep. 2015 Dec 22;5:18670. doi: 10.1038/srep18670. Erratum in: Sci Rep. 2016;6:22205. multiple author names corrected.

28.

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.

Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G.

Oncotarget. 2016 Oct 25;7(43):69412-69419. doi: 10.18632/oncotarget.5136.

29.

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G.

Oncotarget. 2015 Oct 13;6(31):31604-12. doi: 10.18632/oncotarget.5231.

30.

Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses.

Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM.

Lancet Psychiatry. 2015 May;2(5):452-464. doi: 10.1016/S2215-0366(15)00115-7. Epub 2015 Apr 28. Review.

PMID:
26360288
31.

Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.

Santini D, Stumbo L, Spoto C, D'Onofrio L, Pantano F, Iuliani M, Fioramonti M, Zoccoli A, Ribelli G, Virzì V, Vincenzi B, Tonini G.

Breast Cancer Res. 2015 Sep 2;17:121. doi: 10.1186/s13058-015-0634-8. Review.

32.

Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).

Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG.

Clin Cancer Res. 2016 Feb 15;22(4):837-46. doi: 10.1158/1078-0432.CCR-15-1243. Epub 2015 Aug 10.

33.

Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.

Vincenzi B, Stumbo L, Maltese G, Cerbone L, Spalato Ceruso M, Badalamenti G, Santini D, Tonini G, Frezza AM, De Lisi D, Silletta M.

Sci Rep. 2015 Aug 3;5:12077. doi: 10.1038/srep12077.

34.

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G.

PLoS One. 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. eCollection 2015.

35.

Electroporation Enhances Bleomycin Efficacy in Cats with Periocular Carcinoma and Advanced Squamous Cell Carcinoma of the Head.

Spugnini EP, Pizzuto M, Filipponi M, Romani L, Vincenzi B, Menicagli F, Lanza A, De Girolamo R, Lomonaco R, Fanciulli M, Spriano G, Baldi A.

J Vet Intern Med. 2015 Sep-Oct;29(5):1368-75. doi: 10.1111/jvim.13586. Epub 2015 Jul 20.

36.

Emerging drugs for the treatment of bone metastasis.

Pantano F, Iuliani M, Zoccoli A, Fioramonti M, De Lisi D, Fioroni I, Ribelli G, Santoni M, Vincenzi B, Tonini G, Santini D.

Expert Opin Emerg Drugs. 2015;20(4):637-51. doi: 10.1517/14728214.2015.1062876. Epub 2015 Jun 25. Review.

PMID:
26113304
37.

Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.

Vincenzi B, Imperatori M, Picardi A, Vespasiani Gentilucci U, Gallo P, Fausti V, Spalato Ceruso M, Santini D, Tonini G.

Expert Rev Anticancer Ther. 2015;15(8):971-6. doi: 10.1586/14737140.2015.1061937. Epub 2015 Jun 25.

PMID:
26112080
38.

Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials.

Santoni M, Conti A, Andrikou K, Bittoni A, Lanese A, Pistelli M, Pantano F, Vincenzi B, Armento G, Massari F, Tonini G, Cascinu S, Santini D.

Crit Rev Oncol Hematol. 2015 Nov;96(2):206-19. doi: 10.1016/j.critrevonc.2015.05.007. Epub 2015 Jun 10. Review.

PMID:
26070625
39.

Emerging kinase inhibitors of the treatment of gastric cancer.

Vincenzi B, Imperatori M, Silletta M, Marrucci E, Santini D, Tonini G.

Expert Opin Emerg Drugs. 2015 Sep;20(3):479-93. doi: 10.1517/14728214.2015.1051467. Epub 2015 Jun 1. Review.

PMID:
26021342
40.

Pazopanib and pancreatic toxicity: a case report.

Russano M, Vincenzi B, Venditti O, D'Onofrio L, Ratta R, Guida FM, Tonini G, Santini D.

BMC Res Notes. 2015 May 14;8:196. doi: 10.1186/s13104-015-1154-4.

41.

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment.

Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, Berruti A, Scagliotti GV, Tonini G, Santini D.

Oncotarget. 2015 May 20;6(14):12520-8.

42.

Classic Kaposi Sarcoma: to treat or not to treat?

Vincenzi B, D'Onofrio L, Frezza AM, Grasso RF, Fausti V, Santini D, Dei Tos AP, Tonini G.

BMC Res Notes. 2015 Apr 10;8:138. doi: 10.1186/s13104-015-1076-1.

43.

Deregulation of dicer and mir-155 expression in liposarcoma.

Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G.

Oncotarget. 2015 Apr 30;6(12):10586-91.

44.

Role of c-mesenchymal-epithelial transition pathway in gastric cancer.

Fioroni I, Dell'Aquila E, Pantano F, Intagliata S, Caricato M, Vincenzi B, Coppola R, Santini D, Tonini G.

Expert Opin Pharmacother. 2015 Jun;16(8):1195-207. doi: 10.1517/14656566.2015.1037739. Epub 2015 Apr 16. Review.

PMID:
25881479
45.

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D.

J Exp Clin Cancer Res. 2015 Feb 5;34:10. doi: 10.1186/s13046-015-0122-0.

46.

HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer.

Franco R, Collina F, Di Bonito M, Botti G, Montanaro D, Di Maio L, Vincenzi B, Landi G, D'Aiuto M, Caraglia M, Baldi A.

Histol Histopathol. 2015 Jun;30(6):707-14. doi: 10.14670/HH-30.707. Epub 2014 Dec 22.

PMID:
25530301
47.

Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.

Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, Gronchi A, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J.

Eur J Cancer. 2015 Feb;51(3):374-81. doi: 10.1016/j.ejca.2014.11.007. Epub 2014 Dec 16.

PMID:
25529371
48.

Does a Physician's Attitude toward a Patient with Mental Illness Affect Clinical Management of Diabetes? Results from a Mixed-Method Study.

Welch LC, Litman HJ, Borba CP, Vincenzi B, Henderson DC.

Health Serv Res. 2015 Aug;50(4):998-1020. doi: 10.1111/1475-6773.12267. Epub 2014 Dec 9.

49.

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.

Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D.

Pharmacogenomics. 2014 Sep;15(13):1701-15. doi: 10.2217/pgs.14.124. Review.

PMID:
25410895
50.

Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis.

Berardi R, Rinaldi S, Santini D, Vincenzi B, Giampieri R, Maccaroni E, Marcucci F, Francoletti M, Onofri A, Lucarelli A, Pierantoni C, Tonini G, Cascinu S.

Support Care Cancer. 2015 May;23(5):1295-302. doi: 10.1007/s00520-014-2466-y. Epub 2014 Oct 19.

PMID:
25326782

Supplemental Content

Loading ...
Support Center